secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ayala Pharmaceuticals, Inc. (—)
CIK:        0001100397
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0000929638-24-001326
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ayala Pharmaceuticals' CMO departs immediately; CFO agrees to leave June 25
---------------------------------------------------------------------------

- Andres Guttierez, CMO and EVP, departed on March 25, 2024 upon closing of asset sale to Immunome.
- Roy Golan, CFO, agreed to depart on June 25, 2024, per agreement dated March 27, 2024.
- No replacements have been named for either departing officer.
- Departures follow the previously announced Asset Purchase Agreement with Immunome, Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/0000929638-24-001326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-24-001326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer